Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pralsetinib”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Not applicableNot Yet RecruitingNCT07048964
What this trial is testing

A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations

Who this might be right for
Medullary Thyroid Cancer (MTC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40
Large-scale testing (Phase 3)Ended earlyNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Not applicableNot Yet RecruitingNCT07418879
What this trial is testing

A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Who this might be right for
Non-small Cell Lung CancerRET FusionPralsetinib
Fudan University 25
Not applicableApproved For MarketingNCT04204928
What this trial is testing

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid Cancer
Blueprint Medicines Corporation
Large-scale testing (Phase 3)WithdrawnNCT04760288
What this trial is testing

Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Who this might be right for
Medullary Thyroid Cancer
Hoffmann-La Roche
Not applicableUnknownNCT04697446
What this trial is testing

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Blueprint Medicines Corporation 279